Cyclacel Pharmaceuticals, Inc. (CYCC) is a clinical-stage biopharmaceutical company adept in developing innovative small-molecule drugs for the treatment of cancer and other serious diseases. The company, established in 1996 and headquartered in Berkeley Heights, New Jersey, exhibits a productive footprint within the highly competitive biotech industry.
The company’s central mission is dedicated towards the discovery, development, and commercialization of transformational medicinal therapies intended to improve and extend the lives of patients that engage with cancers and other diseases brought forth through cell cycle abnormalities. The cornerstone of Cyclacel’s drug development programs is founded upon the science of cell cycle biology - the expertise which the company has finely cultivated since its inception.
The company boasts a rich portfolio of investigational drugs, such as Sapacitabine (CYC682), a cell cycle modulating nucleoside analog; Seliciclib (CYC202 or R-roscovitine), a CDK (Cyclin dependent kinase) inhibitor that directs the cell cycle progression and transcription regulation; and CYC116, an aurora kinase and VEGFR2 inhibitor. These drugs are developed to address indication areas that are typically characterized by unmet medical needs.
Cyclacel Pharmaceuticals maintains a vigilant focus on specific types of cancer, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and lung cancer. This dedicated approach towards challenging cancers extends the company's commitment towards leveraging their scientific and clinical expertise in the strides made towards creating a meaningful impact on patients' lives.
Cyclacel extended its research alliance with the University of Edinburgh, aiming to identify and validate new therapeutic targets in the TP53/TIGAR pathway, which demonstrates a significant opportunity for the company's concept of synthetic lethality. This strategic alliance reaffirms the underlying prowess of Cyclacel in utilizing academic-industry partnerships.
To assure shareholders, investors, and medical stakeholders, the company underpins its developments and advancements through vigorous clinical trials, assuring the safety and effectiveness of their new drug candidates. The drug candidates' subsequent approval and launch then lead to quality healthcare solutions consistent with the company's primary goal of enhancing patients' disease management and overall quality of life.
Cyclacel Pharmaceuticals, Inc. presents itself as a robust entity within the biopharmaceutical industry. Its cutting-edge therapies, profound expertise in cell cycle biology, robust preclinical and clinical pipeline, strategic alliances, and commitment to patients distinguish the company and set the stage for its sustained growth and promising future impact.